시장보고서

상품코드

1944390

약물 재창출 시장 : 배포 방식별, 치료 영역별, 최종 용도별, 약제 분자별, 어프로치 유형별, 투여 경로별, 국가별, 지역별 - 산업 분석, 시장 규모 및 점유율, 예측(2025-2032년)

Drug Repurposing Market, By Deployment Mode, By Therapeutic Area, By End Use, By Drug Molecules, By Type of Approach, By Route of Administration, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

발행일: 2026년 01월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 349 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

약물 재창출(기존약 재개발) 시장 규모는 2024년에 330억 1,810만 달러로 평가되며, 2025-2032년에 CAGR 4.30%로 확대하고 있습니다.

약물 재창출 시장은 기존 또는 과거에 승인된 의약품의 새로운 치료 용도를 발굴하고 개발하는 데 초점을 맞추고 있으며, 기존 신약개발 방식보다 더 빠르고 비용 효율적인 치료법 개발을 가능하게 합니다. 연구개발비용의 급증과 복잡하고 희귀한 질환에 대한 치료법 개발이 시급하다는 점이 시장 성장의 주요 촉진요인입니다. 새로운 약물-질병 연관성을 발견하기 위한 인공지능(AI)과 RWD(Real World Data) 활용 확대는 주요 시장 동향입니다. 그러나 규제적 불확실성, 지적재산권 제약, 데이터 검증의 문제 등이 큰 장벽으로 작용하고 있습니다. 이러한 장애물에도 불구하고 희귀질환, 종양학 및 신흥 감염질환에 대한 관심이 높아지면서 약물 재창출에 중요한 기회를 제공합니다. 이를 통해 개발 기간 단축, 실패 위험 감소, 기존 의약품 자산의 임상적 가치 극대화를 실현할 수 있습니다.

드래그 리파패싱 시장 역학

의료비 증가가 약물 재창출 시장 성장을 촉진합니다.

세계 의료비 증가는 약물 재창출 시장 성장의 주요 촉진요인입니다. 의료비에는 예방, 진단, 치료, 재활, 의료 행정이 포함되며, 의료비 상승, 기술 발전, 의료 서비스 수요 증가로 인해 증가 추세에 있습니다. 의료비 증가로 인해 조사 활동, 임상시험, 데이터베이스 연구에 대한 투자가 확대되고 있으며, 이는 기존 약물의 새로운 치료 적응증 발굴에 필수적입니다. 이러한 추세는 기존 신약개발에 비해 저렴한 비용과 빠른 대안을 제공하므로 약물 재창출에 크게 기여하고 있습니다. 미국 메디케어-메디케이드 서비스 센터가 2022년 3월 발표한 '2021-2030 국가 의료 지출 보고서'에 따르면 국가 의료 지출은 연평균 5.1%씩 증가하여 2030년까지 약 6조 8,000억 달러에 달할 것으로 예측됩니다. 메디케어 및 메디케이드 지출 증가는 재사용 연구에 대한 자금 공급을 촉진하고 시장 확대를 가속화할 것입니다.

드래그 리파패싱 시장 : 세분화 분석

세계 약물 재창출 시장은 도입 형태, 치료 영역, 최종 용도, 약물 분자, 접근 방식 유형, 투여 경로, 지역에 따라 세분화되어 있습니다.

암 분야는 전 세계에서 높은 암 발병률과 보다 효과적이고 접근하기 쉬운 치료 옵션에 대한 미충족 수요로 인해 시장에서 큰 비중을 차지하고 있습니다. 기존 암 치료제나 원래 비암 영역의 적응증으로 승인된 치료제가 확립된 안전성-유효성 프로파일을 활용하여 새로운 암 치료제로의 적용을 평가받는 사례가 증가하고 있으며, 이를 통해 개발 기간을 단축하고 있습니다. 이 전략은 새로운 암 치료법을 도입하는 데 필요한 비용과 시간을 크게 줄일 수 있습니다. 예를 들어 2024년 12월 UT 사우스웨스턴 연구소 연구진은 다발성골수종 및 림프종에 대한 FDA 승인 치료제가 KRAS 돌연변이 비소세포폐암 환자에서 종양 축소 효과를 보였다고 보고한 바 있습니다. 이와 함께 ReDO 프로젝트와 같은 노력은 효과적이고 독성이 낮은 치료 옵션을 제공하는 데 초점을 맞추고 비암 치료제의 종양학 분야로의 전환을 촉진하고 있습니다.

최종 용도별로는 제약 및 생명공학 기업이 매출의 대부분을 차지하고 있습니다. 이들 기업은 이미 구축된 인프라, 광범위한 R&D 역량, 규제 관련 전문지식을 보유하고 있으며, 기존 약물을 새로운 적응증으로 효과적으로 전환할 수 있습니다. 풍부한 자금력으로 임상시험 자금 조달과 유망한 신약 후보물질 확보가 용이합니다. 또한 의료 공백을 메워야 할 필요성과 저비용 치료법에 대한 수요가 증가함에 따라 이들 기업은 전환 전략을 검토하고 있습니다. 미국 식품의약국(FDA)은 2022년 5월, COVID-19로 인해 다양한 수준의 호흡 보조가 필요한 입원 성인 환자를 위한 치료제로 바리시티닙을 승인했습니다. 이번 승인은 2020년 11월에 발급된 긴급사용허가(EUA)에 이은 것입니다. EUA는 입원 중인 성인 및 소아 환자의 COVID-19 치료에 바리시티닙과 렘데시비르 병용요법을 승인했습니다. 이번 승인은 적응증 기반 COVID-19 치료 임상시험(ACTT-2)의 결과에 기반한 것으로, 병용요법이 입원 환자의 회복 기간을 단축하고 임상 결과를 개선하는 것으로 나타났습니다.

드래그 리파패싱 시장 - 지역별 분석

북미가 시장을 주도하고 있습니다. 이러한 확장은 첨단 연구 인프라, 지원적인 규제 상황, 재사용 의약품의 신속한 승인에 의해 촉진되고 있습니다. 또한 이 지역에서는 다양한 질병에 대한 재사용 의약품 개발을 위해 AI 스타트업, 연구센터, 대형 제약사 간의 강력한 협력이 촉진되고 있습니다. 2025년 8월, Fifty 1 Labs, Inc.의 자회사인 Fifty 1 AI Labs는 우주 의료를 위한 AI를 활용한 약물 재창출 구상 개발을 위해 LUNR Aerospace와 파트너십을 체결했습니다.

미국 드래그 리파패싱 시장 - 국가별 분석

미국은 북미의 주요 시장으로, AI를 활용한 신약개발 플랫폼에 대한 투자를 촉진하는 활발한 제약 및 바이오테크 산업이 주도하고 있습니다. 예를 들어 2025년 9월 매사추세츠에 본사를 둔 라일라 사이언시스(Lila Sciences)는 AI 기반 자율 연구소를 확장하기 위해 시리즈 A 라운드에서 2억 3,500만 달러의 자금 조달을 진행했습니다. 이 자금은 보스턴, 샌프란시스코, 런던에 설치된 라이라의 'AI 사이언스 팩토리' 확장에 사용될 예정입니다. 이 시설에서는 AI 모델이 가설을 세우고, 실험을 수행하고, 그 결과를 통해 학습하고, 처음부터 끝까지 반복적으로 처리합니다. 이 국가의 강력한 자금 조달 환경과 학술기관 및 AI 솔루션 제공 업체와의 성숙한 협력과 결합하여 대규모 재사용 프로그램을 지속적으로 추진하고 있습니다.

The drug repurposing market focuses on identifying and developing new therapeutic uses for existing or previously approved drugs, allowing for faster and more cost-effective treatment development than traditional drug discovery. Rising R&D costs and the urgent need to accelerate therapies for complex and rare diseases are the primary drivers of market growth. The increasing use of artificial intelligence and real-world data to discover novel drug-disease relationships is a major market trend. However, regulatory uncertainties, intellectual property limitations, and data validation challenges all act as significant barriers. Despite these obstacles, a greater emphasis on rare diseases, oncology, and emerging infectious conditions presents significant opportunities for drug repurposing, which reduces development timelines, lowers failure risk, and maximizes the clinical value of existing pharmaceutical assets.

Drug Repurposing Market- Market Dynamics

Rising Healthcare Expenditure Driving Drug Repurposing Market Growth

The increasing level of global healthcare expenditure is a major driver of the drug repurposing market's growth. Healthcare spending includes prevention, diagnosis, treatment, rehabilitation, and healthcare administration, and it is increasing due to rising medical costs, technological advancements, and increased demand for healthcare services. Increased healthcare spending allows for more investment in research activities, clinical trials, and data-driven studies, all of which are critical for discovering new therapeutic indications for existing drugs. This trend benefits drug repurposing significantly because it provides a less expensive and faster alternative to traditional drug discovery. According to the 2021-2030 National Health Expenditure report published by the United States Centers for Medicare & Medicaid Services in March 2022, national health spending is expected to increase at an average annual rate of 5.1%, reaching nearly USD 6.8 trillion by 2030. Rising Medicare and Medicaid spending boosts funding availability for repurposing research, hastening market expansion.

Drug Repurposing Market- Segmentation Analysis:

The Global Drug Repurposing Market is segmented on the basis of Deployment Mode, Therapeutic Area, End Use, Drug Molecules, Type of Approach, Route of Administration, and Region.

Oncology represents a significant share of the market, driven by the high global prevalence of cancer and the substantial unmet need for more effective and accessible treatment options. A growing number of existing oncology drugs, as well as therapies originally approved for non-oncologic indications, are being evaluated for new cancer applications by leveraging their established safety and efficacy profiles to accelerate development timelines. This strategy significantly reduces both the cost and time required to introduce new cancer treatments. For example, in December 2024, researchers at UT Southwestern reported that an FDA-approved therapy for multiple myeloma and lymphoma demonstrated tumor-shrinking effects in patients with KRAS-mutated non-small cell lung cancer. In parallel, initiatives such as the ReDO Project are advancing the repurposing of non-cancer drugs for oncology, with a focus on delivering effective, low-toxicity treatment alternatives.

Based on End Use, Pharmaceutical and biotechnology companies account for the majority of revenue share. These companies have established infrastructure, extensive R&D capabilities, and regulatory expertise, allowing them to effectively repurpose existing drugs for new indications. Their vast financial resources make it easier to fund clinical trials and acquire promising drug candidates. Furthermore, the growing need to fill gaps in medical care and the demand for low-cost therapies have prompted these companies to investigate repurposing strategies. The United States Food and Drug Administration (FDA) approved baricitinib in May 2022 for the treatment of hospitalized adults who require varying degrees of respiratory support as a result of COVID-19. This approval followed an earlier Emergency Use Authorization (EUA) issued in November 2020 for the combination of baricitinib and remdesivir in the treatment of COVID-19 in hospitalized adults and pediatric patients. The approval was based on results from the Adaptive COVID-19 Treatment Trial (ACTT-2), which showed that the combination therapy shortened recovery time and improved clinical outcomes in hospitalized patients..

Drug Repurposing Market- Geographical Insights

North America dominates the market. The expansion is fueled by advanced research infrastructure, supportive regulatory landscapes, and faster approval for repurposed drugs. In addition, this region is promoting strong collaborations between AI startups, research centers, and large pharmaceutical companies to develop repurposed drugs for various diseases. In August 2025, Fifty 1 AI Labs, a subsidiary of Fifty 1 Labs, Inc., collaborated with LUNR Aerospace to develop AI-powered drug repurposing initiatives for space medicine.

United States Drug Repurposing Market- Country Insights

The United States is the major North American market, driven by a thriving pharmaceutical and biotechnology industry that is investing in AI-powered drug discovery platforms. For example, in September 2025, Massachusetts-based Lila Sciences raised USD 235 million in a Series A round to expand its AI-powered autonomous laboratories. The funds are raised to expand Lila's "AI Science Factories" in Boston, San Francisco, and London, where AI models develop hypotheses, run experiments, learn from results, and iterate from start to finish. The nation's strong financing environment, combined with mature collaborations between academia and AI solution providers, continues to drive large-scale repurposing programs.

Drug Repurposing Market- Competitive Landscape:

The drug repurposing market is distinguished by collaborations among pharmaceutical companies, biotech firms, research institutions, and technology providers aimed at discovering new therapeutic applications for existing medications. Strategic partnerships, licensing agreements, and investments in advanced computational platforms that accelerate drug repurposing research all have an impact on competition. Companies are increasingly relying on artificial intelligence, real-world evidence, and big data analytics to improve target identification, streamline clinical validation, and lower development costs. Regulatory alignment and shared research frameworks also have an impact on competitive positioning. Novartis AG, Pfizer Inc., Eli Lilly and Company, and Bayer AG are key players driving innovation and commercial activity in the drug repurposing market. These organizations use extensive compound libraries, global R&D capabilities, and strategic alliances to broaden their repurposed drug portfolios and increase market visibility.

In April 2025, Novartis agreed to acquire Regulus Therapeutics, a San Diego-based clinical-stage biopharmaceutical company focused on microRNA therapies. Faburden, Regulus' leading asset, targets miR-17 and has the potential to be a first-in-class treatment for autosomal dominant polycystic kidney disease (ADPKD). This acquisition complements Novartis' focus on renal disease and will increase its expertise in this therapeutic area. The acquisition expands Novartis' portfolio by incorporating novel approaches to treating kidney diseases.

Recent Developments:

In April 2025, Qualthera Health Corporation, which is dedicated to establishing a nationwide network of quality, patient-centered compounding pharmacies, has announced the official launch of Qualthera Pharmaceuticals Ltd. Co., a research-driven subsidiary focused on drug repurposing and innovative delivery systems. This expansion is a significant step forward in accelerating pharmaceutical innovation by leveraging real-world patient insights to create new therapies with streamlined development.

In June 2024, BioXcel Therapeutics used artificial intelligence-based drug repurposing to discover new applications for drug candidates that had stalled in development. The company accelerates therapeutic innovation by integrating approved and established drugs, clinically validated candidates, big data, and proprietary machine learning algorithms. It is focused on research and development costs, market access, and growth in neurology and immuno-oncology within the drug repurposing market.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DRUG REPURPOSING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Eli Lilly and Company
GSK plc
Amgen Inc.
Biogen Inc.
Pfizer Inc.
Roche Holding AG
Novartis AG
AbbVie
Amgen
Boehringer Ingelheim
Cyclica
GlaxoSmithKline
Vertex Pharmaceuticals
Melior Discovery
Pharnext
Recursion Pharmaceuticals
Revolution Medicines
Sanofi
Schwarz Pharma
Valence Discovery
Bayer AG
Teva Pharmaceutical
Others

GLOBAL DRUG REPURPOSING MARKET, BY DEPLOYMENT MODE- MARKET ANALYSIS, 2019 - 2032

On-premises
Cloud-based

GLOBAL DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

Oncology
Cardiovascular Diseases
Infectious Diseases
Rare Diseases
Neurology
Immunology
Metabolic Disorders
Others

GLOBAL DRUG REPURPOSING MARKET, BY END USE- MARKET ANALYSIS, 2019 - 2032

Contract Research Organizations (CROs)
Pharmaceutical & Biotechnology Companies
Healthcare Providers
Academic & Research Institutes
Others

GLOBAL DRUG REPURPOSING MARKET, BY DRUG MOLECULES- MARKET ANALYSIS, 2019 - 2032

Peptides
Biologics
Vaccines
Conventional Small Molecules
Others

GLOBAL DRUG REPURPOSING MARKET, BY TYPE OF APPROACH- MARKET ANALYSIS, 2019 - 2032

Target-centric
Disease-centric
Drug-centric

GLOBAL DRUG REPURPOSING MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Intravenous
Oral
Other routes of administration

GLOBAL DRUG REPURPOSING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Drug Repurposing Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Drug Repurposing Market Snippet by Deployment Mode
- 2.1.2. Drug Repurposing Market Snippet by Therapeutic Area
- 2.1.3. Drug Repurposing Market Snippet by End Use
- 2.1.4. Drug Repurposing Market Snippet by Drug Molecules
- 2.1.5. Drug Repurposing Market Snippet by Type of Approach
- 2.1.6. Drug Repurposing Market Snippet by Route of Administration
- 2.1.7. Drug Repurposing Market Snippet by Country
- 2.1.8. Drug Repurposing Market Snippet by Region
2.2. Competitive Insights

3. Drug Repurposing Key Market Trends

3.1. Drug Repurposing Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Drug Repurposing Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Drug Repurposing Market Opportunities
3.4. Drug Repurposing Market Future Trends

4. Drug Repurposing Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Drug Repurposing Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Drug Repurposing Market Landscape

6.1. Drug Repurposing Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Drug Repurposing Market - By Deployment Mode

7.1. Overview
- 7.1.1. Segment Share Analysis, By Deployment Mode, 2024 & 2032 (%)
- 7.1.2. On-premises
- 7.1.3. Cloud-based

8. Drug Repurposing Market - By Therapeutic Area

8.1. Overview
- 8.1.1. Segment Share Analysis, By Therapeutic Area, 2024 & 2032 (%)
- 8.1.2. Oncology
- 8.1.3. Cardiovascular Diseases
- 8.1.4. Infectious Diseases
- 8.1.5. Rare Diseases
- 8.1.6. Neurology
- 8.1.7. Immunology
- 8.1.8. Metabolic Disorders
- 8.1.9. Others

9. Drug Repurposing Market - By End Use

9.1. Overview
- 9.1.1. Segment Share Analysis, By End Use, 2024 & 2032 (%)
- 9.1.2. Contract Research Organizations (CROs)
- 9.1.3. Pharmaceutical & Biotechnology Companies
- 9.1.4. Healthcare Providers
- 9.1.5. Academic & Research Institutes
- 9.1.6. Others

10. Drug Repurposing Market - By Drug Molecules

10.1. Overview
- 10.1.1. Segment Share Analysis, By Drug Molecules, 2024 & 2032 (%)
- 10.1.2. Peptides
- 10.1.3. Biologics
- 10.1.4. Vaccines
- 10.1.5. Conventional Small Molecules
- 10.1.6. Others

11. Drug Repurposing Market - By Type of Approach

11.1. Overview
- 11.1.1. Segment Share Analysis, By Type of Approach, 2024 & 2032 (%)
- 11.1.2. Target-centric
- 11.1.3. Disease-centric
- 11.1.4. Drug-centric

12. Drug Repurposing Market - By Route of Administration

12.1. Overview
- 12.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
- 12.1.2. Intravenous
- 12.1.3. Oral
- 12.1.4. Other routes of administration

13. Drug Repurposing Market- By Geography

13.1. Introduction
- 13.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
13.2. North America
- 13.2.1. Overview
- 13.2.2. Drug Repurposing Key Manufacturers in North America
- 13.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 13.2.4. North America Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
- 13.2.5. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 13.2.6. North America Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 13.2.7. North America Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
- 13.2.8. North America Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
- 13.2.9. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.2.10. U.S.
  - 13.2.10.1. Overview
  - 13.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.2.10.3. U.S. Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.2.10.4. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.2.10.5. U.S. Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.2.10.6. U.S. Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.2.10.7. U.S. Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.2.10.8. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.2.11. Canada
  - 13.2.11.1. Overview
  - 13.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.2.11.3. Canada Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.2.11.4. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.2.11.5. Canada Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.2.11.6. Canada Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.2.11.7. Canada Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.2.11.8. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.3. Europe
- 13.3.1. Overview
- 13.3.2. Drug Repurposing Key Manufacturers in Europe
- 13.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 13.3.4. Europe Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
- 13.3.5. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 13.3.6. Europe Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 13.3.7. Europe Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
- 13.3.8. Europe Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
- 13.3.9. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.10. Germany
  - 13.3.10.1. Overview
  - 13.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.10.3. Germany Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.3.10.4. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.3.10.5. Germany Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.3.10.6. Germany Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.3.10.7. Germany Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.3.10.8. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.11. UK
  - 13.3.11.1. Overview
  - 13.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.11.3. UK Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.3.11.4. UK Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.3.11.5. UK Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.3.11.6. UK Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.3.11.7. UK Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.3.11.8. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.12. France
  - 13.3.12.1. Overview
  - 13.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.12.3. France Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.3.12.4. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.3.12.5. France Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.3.12.6. France Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.3.12.7. France Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.3.12.8. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.13. Italy
  - 13.3.13.1. Overview
  - 13.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.13.3. Italy Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.3.13.4. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.3.13.5. Italy Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.3.13.6. Italy Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.3.13.7. Italy Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.3.13.8. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.14. Spain
  - 13.3.14.1. Overview
  - 13.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.14.3. Spain Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.3.14.4. Spain Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.3.14.5. Spain Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.3.14.6. Spain Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.3.14.7. Spain Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.3.14.8. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.15. The Netherlands
  - 13.3.15.1. Overview
  - 13.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.15.3. The Netherlands Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.3.15.4. The Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.3.15.5. The Netherlands Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.3.15.6. The Netherlands Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.3.15.7. The Netherlands Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.3.15.8. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.16. Sweden
  - 13.3.16.1. Overview
  - 13.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.16.3. Sweden Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.3.16.4. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.3.16.5. Sweden Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.3.16.6. Sweden Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.3.16.7. Sweden Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.3.16.8. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.17. Russia
  - 13.3.17.1. Overview
  - 13.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.17.3. Russia Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.3.17.4. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.3.17.5. Russia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.3.17.6. Russia Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.3.17.7. Russia Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.3.17.8. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.18. Poland
  - 13.3.18.1. Overview
  - 13.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.18.3. Poland Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.3.18.4. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.3.18.5. Poland Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.3.18.6. Poland Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.3.18.7. Poland Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.3.18.8. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.3.19. Rest of Europe
  - 13.3.19.1. Overview
  - 13.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.3.19.3. Rest of the Europe Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.3.19.4. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.3.19.5. Rest of the Europe Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.3.19.6. Rest of the Europe Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.3.19.7. Rest of the Europe Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.3.19.8. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.4. Asia Pacific (APAC)
- 13.4.1. Overview
- 13.4.2. Drug Repurposing Key Manufacturers in Asia Pacific
- 13.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 13.4.4. APAC Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
- 13.4.5. APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 13.4.6. APAC Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 13.4.7. APAC Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
- 13.4.8. APAC Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
- 13.4.9. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.10. China
  - 13.4.10.1. Overview
  - 13.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.10.3. China Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.4.10.4. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.4.10.5. China Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.4.10.6. China Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.4.10.7. China Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.4.10.8. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.11. India
  - 13.4.11.1. Overview
  - 13.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.11.3. India Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.4.11.4. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.4.11.5. India Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.4.11.6. India Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.4.11.7. India Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.4.11.8. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.12. Japan
  - 13.4.12.1. Overview
  - 13.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.12.3. Japan Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.4.12.4. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.4.12.5. Japan Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.4.12.6. Japan Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.4.12.7. Japan Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.4.12.8. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.13. South Korea
  - 13.4.13.1. Overview
  - 13.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.13.3. South Korea Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.4.13.4. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.4.13.5. South Korea Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.4.13.6. South Korea Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.4.13.7. South Korea Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.4.13.8. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.14. Australia
  - 13.4.14.1. Overview
  - 13.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.14.3. Australia Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.4.14.4. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.4.14.5. Australia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.4.14.6. Australia Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.4.14.7. Australia Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.4.14.8. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.15. Indonesia
  - 13.4.15.1. Overview
  - 13.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.15.3. Indonesia Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.4.15.4. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.4.15.5. Indonesia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.4.15.6. Indonesia Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.4.15.7. Indonesia Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.4.15.8. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.16. Thailand
  - 13.4.16.1. Overview
  - 13.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.16.3. Thailand Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.4.16.4. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.4.16.5. Thailand Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.4.16.6. Thailand Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.4.16.7. Thailand Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.4.16.8. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.17. Philippines
  - 13.4.17.1. Overview
  - 13.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.17.3. Philippines Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.4.17.4. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.4.17.5. Philippines Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.4.17.6. Philippines Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.4.17.7. Philippines Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.4.17.8. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.4.18. Rest of APAC
  - 13.4.18.1. Overview
  - 13.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.4.18.3. Rest of APAC Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.4.18.4. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.4.18.5. Rest of APAC Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.4.18.6. Rest of APAC Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.4.18.7. Rest of APAC Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.4.18.8. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.5. Latin America (LATAM)
- 13.5.1. Overview
- 13.5.2. Drug Repurposing Key Manufacturers in Latin America
- 13.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 13.5.4. LATAM Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
- 13.5.5. LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 13.5.6. LATAM Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 13.5.7. LATAM Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
- 13.5.8. LATAM Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
- 13.5.9. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.5.10. Brazil
  - 13.5.10.1. Overview
  - 13.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.5.10.3. Brazil Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.5.10.4. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.5.10.5. Brazil Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.5.10.6. Brazil Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.5.10.7. Brazil Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.5.10.8. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.5.11. Mexico
  - 13.5.11.1. Overview
  - 13.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.5.11.3. Mexico Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.5.11.4. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.5.11.5. Mexico Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.5.11.6. Mexico Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.5.11.7. Mexico Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.5.11.8. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.5.12. Argentina
  - 13.5.12.1. Overview
  - 13.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.5.12.3. Argentina Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.5.12.4. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.5.12.5. Argentina Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.5.12.6. Argentina Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.5.12.7. Argentina Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.5.12.8. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.5.13. Colombia
  - 13.5.13.1. Overview
  - 13.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.5.13.3. Colombia Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.5.13.4. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.5.13.5. Colombia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.5.13.6. Colombia Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.5.13.7. Colombia Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.5.13.8. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.5.14. Rest of LATAM
  - 13.5.14.1. Overview
  - 13.5.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.5.14.3. Rest of LATAM Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.5.14.4. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.5.14.5. Rest of LATAM Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.5.14.6. Rest of LATAM Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.5.14.7. Rest of LATAM Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.5.14.8. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.6. Middle East and Africa
- 13.6.1. Overview
- 13.6.2. Drug Repurposing Key Manufacturers in Middle East and Africa
- 13.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 13.6.4. Middle East and Africa Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
- 13.6.5. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 13.6.6. Middle East and Africa Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 13.6.7. Middle East and Africa Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
- 13.6.8. Middle East and Africa Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
- 13.6.9. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.6.10. Saudi Arabia
  - 13.6.10.1. Overview
  - 13.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.6.10.3. Saudi Arabia Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.6.10.4. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.6.10.5. Saudi Arabia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.6.10.6. Saudi Arabia Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.6.10.7. Saudi Arabia Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.6.10.8. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.6.11. United Arab Emirates
  - 13.6.11.1. Overview
  - 13.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.6.11.3. United Arab Emirates Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.6.11.4. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.6.11.5. United Arab Emirates Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.6.11.6. United Arab Emirates Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.6.11.7. United Arab Emirates Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.6.11.8. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.6.12. Israel
  - 13.6.12.1. Overview
  - 13.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.6.12.3. Israel Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.6.12.4. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.6.12.5. Israel Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.6.12.6. Israel Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.6.12.7. Israel Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.6.12.8. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.6.13. Turkey
  - 13.6.13.1. Overview
  - 13.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.6.13.3. Turkey Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.6.13.4. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.6.13.5. Turkey Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.6.13.6. Turkey Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.6.13.7. Turkey Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.6.13.8. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.6.14. Algeria
  - 13.6.14.1. Overview
  - 13.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.6.14.3. Algeria Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.6.14.4. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.6.14.5. Algeria Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.6.14.6. Algeria Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.6.14.7. Algeria Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.6.14.8. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.6.15. Egypt
  - 13.6.15.1. Overview
  - 13.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.6.15.3. Egypt Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.6.15.4. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.6.15.5. Egypt Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.6.15.6. Egypt Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.6.15.7. Egypt Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.6.15.8. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 13.6.16. Rest of MEA
  - 13.6.16.1. Overview
  - 13.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 13.6.16.3. Rest of MEA Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
  - 13.6.16.4. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 13.6.16.5. Rest of MEA Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  - 13.6.16.6. Rest of MEA Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
  - 13.6.16.7. Rest of MEA Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
  - 13.6.16.8. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)

14. Key Vendor Analysis- Drug Repurposing Industry

14.1. Competitive Benchmarking
- 14.1.1. Competitive Dashboard
- 14.1.2. Competitive Positioning
14.2. Company Profiles
- 14.2.1. Eli Lilly and Company
- 14.2.2. GSK plc
- 14.2.3. Amgen Inc.
- 14.2.4. Biogen Inc.
- 14.2.5. Pfizer Inc.
- 14.2.6. Roche Holding AG
- 14.2.7. Novartis AG
- 14.2.8. AbbVie
- 14.2.9. Amgen
- 14.2.10. Boehringer Ingelheim
- 14.2.11. Cyclica
- 14.2.12. GlaxoSmithKline
- 14.2.13. Vertex Pharmaceuticals
- 14.2.14. Melior Discovery
- 14.2.15. Pharnext
- 14.2.16. Recursion Pharmaceuticals
- 14.2.17. Revolution Medicines
- 14.2.18. Sanofi
- 14.2.19. Schwarz Pharma
- 14.2.20. Valence Discovery
- 14.2.21. Bayer AG
- 14.2.22. Teva Pharmaceutical
- 14.2.23. Others

15. 360 Degree Analyst View

16. Appendix

16.1. Research Methodology
16.2. References
16.3. Abbreviations
16.4. Disclaimer
16.5. Contact Us

약물 재창출 시장 : 배포 방식별, 치료 영역별, 최종 용도별, 약제 분자별, 어프로치 유형별, 투여 경로별, 국가별, 지역별 - 산업 분석, 시장 규모 및 점유율, 예측(2025-2032년)

Drug Repurposing Market, By Deployment Mode, By Therapeutic Area, By End Use, By Drug Molecules, By Type of Approach, By Route of Administration, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

드래그 리파패싱 시장 : 세분화 분석

목차

제1장 약물 재창출 시장의 개요

제2장 개요

제3장 약물 재창출의 주요 시장 동향

제4장 약물 재창출 시장 : 산업 분석

제5장 약물 재창출 시장 : 높아지는 지정학적 긴장의 영향

제6장 약물 재창출 시장 구도

제7장 약물 재창출 시장 : 배포 방식별

제8장 약물 재창출 시장 : 치료 영역별

제9장 약물 재창출 시장 : 최종 용도별

제10장 약물 재창출 시장 : 약제 분자별

제11장 약물 재창출 시장 : 어프로치 유형별

제12장 약물 재창출 시장 : 투여 경로별

제13장 약물 재창출 시장 : 지역별

제14장 주요 벤더 분석 : 약물 재창출 업계

제15장 AnalystView의 전방위적 분석